This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): pregabalin immediate release, Pregabalin Pfizer, Lyrica CV, Lyrica IR
Description: Lyrica binds with high affinity to the alpha2-delta site, an auxiliary subunit of voltage-gated calcium channels, in central nervous system tissues. Although the mechanism of action is unknown, preclinical results with compounds structurally related to Lyrica (such as gabapentin) suggest that binding to the alpha2-delta subunit may be involved in Lyrica's antinociceptive and antiseizure effects. In vitro, Lyrica reduces the calcium-dependent release of several neurotransmitters, possibly by modulation of calcium channel function.
While Lyrica is a structural derivative of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), it does not bind directly to GABAA, GABAB, or benzodiazepine receptors, does not augment GABAA responses in cultured neurons, does not alter rat brain GABA concentration or have acute effects on GABA uptake or degradation. However, in cultured neurons prolonged application of Lyrica increases the density of GABA transporter protein and increases the rate of functional GABA transport.
Pfizer is also developing Lyrica CR, a controlled release (once-a-day dosing) verison of Lyrica.
Revenue splits for this drug are BioMedTracker estimates.
Please note Lyrica's Neuropathic Pain model encompasses revenue in neuropathic pain associated with DPN and PHN. Also, the Pain Indications model reflects revenue from various pain indications for which Lyrica is not specifically approved.
Lyrica was originally developed by Pfizer.
In December 2007, Northwestern University sold a portion of its worldwide royalty interest in Lyrica to Royalty Pharma for $700 million in cash. The percentage of the Universitys interest in the royalty payments that was sold today is not being disclosed, other than to say that Northwestern retains a large portion of the royalty rights.
In September 2009, Pfizer and Eisai entered into an agreement to co-promote Lyrica in Japan. Assuming Lyrica is granted approval, the agreement will continue in force until July 2022.
In April 2010, Impax announced that it amended its 2008 co-promotion agreement with Wyeth, now a wholly...See full deal structure in Biomedtracker
Partners: Eisai Co., Ltd. Impax Laboratories, Inc. Royalty Pharma AG
Pink Sheet Lyrica FDA Reviewers
Pink Sheet Lyrica Clinical Development
Additional information available to subscribers only: